SBTX insider filings
Silverback Therapeutics, Inc. — 48 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-08-09. Screen SBTX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for SBTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Silverback Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-08-09 | 4 | Shawver Laura — Chief Executive Officer, Director | Option exercise (M): 78,740 @ $1.27 · Option exercise (M): 78,740 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Koehler Maria — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Islam Saqib — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Powell Andrew Kenneth William — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | HERSHBERG ROBERT — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | CAPPS VICKIE L — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | ROOT JONATHAN D — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-05-04 | 4 | Piazza Jonathan — Chief Financial Officer | Grant/award (A): 43,691 @ $0 · Grant/award (A): 87,383 (derivative) @ $0 | EDGAR |
| 2022-05-04 | 4 | Odegard Valerie — President and CSO | Grant/award (A): 45,233 @ $0 · Grant/award (A): 90,467 (derivative) @ $0 | EDGAR |
| 2022-05-04 | 4 | Hunder Naomi — Chief Medical Officer | Grant/award (A): 43,177 @ $0 · Grant/award (A): 86,355 (derivative) @ $0 | EDGAR |
| 2022-05-04 | 4 | Hawkinson Russ — Sr. Vice President of Finance | Grant/award (A): 28,335 @ $0 · Grant/award (A): 56,670 (derivative) @ $0 | EDGAR |
| 2022-05-04 | 4 | Shawver Laura — Chief Executive Officer, Director | Grant/award (A): 68,107 @ $0 · Grant/award (A): 136,214 (derivative) @ $0 | EDGAR |
| 2022-03-18 | 4 | ROOT JONATHAN D — Director | Purchase (P): 350 @ $52.07 · Purchase (P): 2,014 @ $8.85 | EDGAR |
| 2022-02-24 | 4/A | Hawkinson Russ — Sr. Vice President of Finance | Purchase (P): 200 @ $21 | EDGAR |
| 2022-02-02 | 4 | Hawkinson Russ — Sr. Vice President of Finance | Grant/award (A): 7,500 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 · Grant/award (A): 28,500 (derivative) @ $0 | EDGAR |
| 2022-02-02 | 4 | Piazza Jonathan — Chief Financial Officer | Grant/award (A): 11,250 @ $0 · Grant/award (A): 67,500 (derivative) @ $0 · Grant/award (A): 42,750 (derivative) @ $0 | EDGAR |
| 2022-02-02 | 4 | Hunder Naomi — Chief Medical Officer | Grant/award (A): 11,250 @ $0 · Grant/award (A): 67,500 (derivative) @ $0 · Grant/award (A): 42,750 (derivative) @ $0 | EDGAR |
| 2022-02-02 | 4 | Odegard Valerie — President and CSO | Grant/award (A): 16,406 @ $0 · Grant/award (A): 98,438 (derivative) @ $0 · Grant/award (A): 49,875 (derivative) @ $0 | EDGAR |
| 2022-02-02 | 4 | Shawver Laura — Chief Executive Officer, Director | Grant/award (A): 27,500 @ $0 · Grant/award (A): 165,000 (derivative) @ $0 · Grant/award (A): 104,500 (derivative) @ $0 | EDGAR |
| 2021-12-15 | 4 | ROOT JONATHAN D — Director | Other (J): 2,069,167 · Other (J): 105,012 | EDGAR |
| 2021-09-21 | 4 | Islam Saqib — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-09-21 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-09-21 | 4 | Powell Andrew Kenneth William — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-09-21 | 4 | HERSHBERG ROBERT — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-09-21 | 4 | CAPPS VICKIE L — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-09-21 | 4 | ROOT JONATHAN D — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-03-16 | 4 | Koehler Maria — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2020-12-08 | 4 | Alexandria Venture Investments, LLC — 10% owner | Conversion (C): 699,412 · Conversion (C): 1,428,570 (derivative) · Conversion (C): 1,168,347 (derivative) | EDGAR |
| 2020-12-08 | 4 | Hawkinson Russ — Sr. Vice President of Finance | Purchase (P): 238 @ $21 | EDGAR |
| 2020-12-08 | 4 | Piazza Jonathan — Chief Financial Officer | Purchase (P): 11,904 @ $21 | EDGAR |
| 2020-12-08 | 4 | Schroeder Thilo — Director | Purchase (P): 238,096 @ $21 · Conversion (C): 1,246,870 · Conversion (C): 425,063 · Conversion (C): 4,629,630 (derivative) @ $0 · Conversion (C): 1,578,259 (derivative) @ $0 | EDGAR |
| 2020-12-08 | 4 | Presidio Management Group XII, L.L.C. — 10% owner U.S. Venture Partners XII, L.P. — 10% owner U.S. Venture Partners XII-A, L.P. — 10% owner Tansey Casey M — 10% owner | Conversion (C): 1,779,969 · Conversion (C): 289,198 · Conversion (C): 90,335 · Conversion (C): 14,677 · Purchase (P): 47,619 @ $21 · Conversion (C): 6,609,027 (derivative) @ $0 · +3 more | EDGAR |
| 2020-12-08 | 4 | Thompson Peter A. — Director, 10% owner | Purchase (P): 238,100 @ $21 · Conversion (C): 3,462,737 · Conversion (C): 2,493,741 · Conversion (C): 1,055,287 · Purchase (P): 952,377 @ $21 · Conversion (C): 12,857,142 (derivative) @ $0 · +2 more | EDGAR |
| 2020-12-08 | 4 | CAPPS VICKIE L — Director | Purchase (P): 9,523 @ $21 | EDGAR |
| 2020-12-08 | 4 | ROOT JONATHAN D — Director | Purchase (P): 95,238 @ $21 · Conversion (C): 1,779,969 · Conversion (C): 289,198 · Conversion (C): 90,335 · Conversion (C): 14,677 · Conversion (C): 6,609,027 (derivative) @ $0 · +3 more | EDGAR |
| 2020-12-08 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VI LLC — Director, 10% owner ORBIMED CAPITAL LLC — Director, 10% owner | Purchase (P): 238,100 @ $21 · Conversion (C): 3,462,737 · Conversion (C): 2,493,741 · Conversion (C): 1,055,287 · Purchase (P): 952,377 @ $21 · Conversion (C): 12,857,142 (derivative) @ $0 · +2 more | EDGAR |
| 2020-12-07 | 4 | Odegard Valerie — President and CSO | Grant/award (A): 364,904 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Piazza Jonathan — Chief Financial Officer | Grant/award (A): 74,730 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Hunder Naomi — Chief Medical Officer | Grant/award (A): 231,071 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Hawkinson Russ — Sr. Vice President of Finance | Grant/award (A): 102,038 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Islam Saqib — Director | Grant/award (A): 69,753 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Shawver Laura — Chief Executive Officer, Director | Grant/award (A): 562,631 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 38,270 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | Powell Andrew Kenneth William — Director | Grant/award (A): 21,009 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | HERSHBERG ROBERT — Director | Grant/award (A): 73,251 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | CAPPS VICKIE L — Director | Grant/award (A): 38,405 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | ROOT JONATHAN D — Director, 10% owner | Grant/award (A): 38,270 (derivative) @ $0 | EDGAR |
Recent 8-K events — Silverback Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-25 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SBTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs